Teriparatide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Teriparatide: From Osteoporosis to Pregnancy and Lactation-Associated Osteoporosis
One-Sentence Summary
Teriparatide (rhPTH 1-34, brand FORTEO) is an established bone-anabolic agent for osteoporosis. Among 10 TxGNN-predicted indications screened for this drug, Pregnancy and Lactation-Associated Osteoporosis (PLO) is the only one supported by real clinical evidence — 2 clinical trials and 20 publications, including several teriparatide-specific case series and two systematic reviews. The other 9 candidates (e.g. duodenal ulcer, Worth syndrome, esophageal disease) returned no or only incidental/adverse-event literature and are classified L4–L5 "Hold" — they are noted but not the focus of this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Osteoporosis (bone-anabolic agent; approved as FORTEO) |
| Predicted New Indication | Pregnancy and Lactation-Associated Osteoporosis (PLO) |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L3 |
| TFDA Market Status | 未上市 (Not marketed / no license on file) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (data gap, high severity). Based on known information from the underlying trial evidence, teriparatide is a recombinant human parathyroid hormone [PTH(1-34)] with bone-forming (anabolic) activity, and "has been approved for the treatment of osteoporosis as FORTEO by Eli Lilly & Co." with "numerous studies [verifying] its effectiveness in increasing bone mass" (NCT00277706).
PLO is not a mechanistically distinct disease — it is a rare, premenopausal phenotype of osteoporosis triggered by the calcium/bone-turnover demands of late pregnancy and lactation, presenting with vertebral fragility fractures. Because the underlying pathology (low bone mass, fracture risk) is the same as in the approved indication, the pharmacological rationale for using an anabolic bone agent is direct rather than speculative — this is best understood as a population extension of the existing mechanism (postmenopausal osteoporosis → premenopausal, pregnancy/lactation-related osteoporosis) rather than a novel mechanistic repurposing.
This is corroborated by the literature: teriparatide is already described in multiple reviews as one of the preferred off-label treatment options for PLO (PMID 28084543), and dedicated case series/systematic reviews document its use and outcomes in this population (PMID 34132853, 35903718, 37708365).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02440581 | N/A | Completed | 141 | "Renal Osteodystrophy: A Fresh Approach" — studies bone loss/CKD-associated osteoporosis; population is renal osteodystrophy, not PLO specifically; provides indirect PTH-pathway/bone-metabolism overlap only (relevance grade C) |
| NCT00277706 | Phase 1 | Completed | 40 | Impact of PTH(1-34) on osseous regeneration in the oral cavity; confirms FORTEO's approved bone-anabolic mechanism but studies periodontal bone regeneration, not PLO (relevance grade C) |
No trial in this evidence pack was designed specifically for PLO; the two identified trials contribute only background pharmacology/safety context for PTH(1-34), consistent with PLO's rarity and the lack of dedicated RCTs noted throughout the literature below.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37708365 | 2024 | Systematic Review & Meta-analysis | J Clin Endocrinol Metab | Comparative effectiveness of therapeutic interventions (incl. teriparatide) in PLO; notes optimal management remains undefined |
| 40205203 | 2025 | Systematic Review & Meta-analysis | Osteoporos Int | 35 studies / 943 patients; vertebral fractures and back pain common; treatment-response analysis inconclusive due to limited data |
| 34132853 | 2021 | Case series (multicenter retrospective cohort) | Calcif Tissue Int | 19 women with PLO treated with teriparatide (20 μg/day) + calcium vs. conventional management — assessed BMD and trabecular bone score |
| 35903718 | 2022 | Case series | Geburtshilfe Frauenheilkd | 47 women with PLO and vertebral fractures treated with teriparatide; effect on subsequent fracture and BMD |
| 34037833 | 2021 | Retrospective cohort | Calcif Tissue Int | BMD outcomes after teriparatide discontinuation, with vs. without sequential antiresorptive therapy in PLO |
| 39008200 | 2024 | Review (teriparatide-focused) | Endocrine | Effective strategies for PLO with specific focus on teriparatide use; notes lack of RCTs and poorly defined treatment strategies |
| 36764958 | 2023 | Case report | Calcif Tissue Int | Bone microarchitecture/strength changes during combined teriparatide + zoledronic acid treatment in severe PLO |
| 33620518 | 2022 | Review | Calcif Tissue Int | General PLO overview — pathophysiology, presentation, vertebral fracture risk |
| 37175006 | 2023 | Narrative Review | Diagnostics (Basel) | Diagnostic/management gaps in PLO; individualized strategy needed |
| 28084543 | 2017 | Review | Z Rheumatol | States teriparatide and bisphosphonates "seem to be the best option" for PLO |
Finland Market Information
No TFDA marketing authorization is currently on file for teriparatide in this dataset (0 licenses, status: 未上市 / not marketed). This is itself a blocking data gap (DG001) for full safety evaluation and should be resolved via TFDA package-insert retrieval before proceeding further.
Safety Considerations
Please refer to the package insert for safety information. No structured warnings, contraindications, or drug-interaction data were returned for this drug in the current evidence pack (DDI query status: not found).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: PLO shares direct pathophysiology and mechanism with teriparatide's approved osteoporosis indication, and off-label use is already documented across two systematic reviews and multiple teriparatide-specific case series (up to 47 patients). However, no RCT exists (PLO is rare and difficult to randomize), and TFDA safety/label data for this drug is entirely missing.
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism of action detail from DrugBank
- Drug-drug interaction profile (currently not found)
- A pregnancy/lactation-specific safety and monitoring plan, given the target population
- Ongoing surveillance of the 9 other TxGNN-flagged candidates (L4–L5, Hold) is not warranted at this time — none returned supportive evidence, and one (esophageal disease) surfaced only adverse-event literature (e.g. calcinosis cutis worsening, PMID 26992073) rather than efficacy signal.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.